ImmunityBio, Inc. has received marketing authorization from the Emirates Drug Establishment for ANKTIVA across two cancer indications, giving the interleukin-15 receptor agonist its broadest regulatory label so far. The United Arab Emirates decision covers ANKTIVA with Bacillus Calmette-Guérin for adults with BCG-unresponsive non-muscle invasive bladder cancer, including carcinoma in situ and papillary-only disease, as well as ANKTIVA with an immune checkpoint inhibitor for adults with previously treated metastatic non-small cell lung cancer.
The authorization is commercially and strategically significant because it goes beyond the current United States label, which covers BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors, but does not include papillary-only disease or lung cancer. The UAE has therefore become an important regulatory test market for ImmunityBio’s attempt to develop ANKTIVA from a bladder cancer product into a multi-indication immunotherapy franchise.
The decision also creates a more complicated evidence story. The bladder cancer authorization draws on longer-term findings from the QUILT-3.032 programme, while the metastatic lung cancer indication is supported by a relatively small, single-arm Phase 2 study. Authorization gives ImmunityBio a route to market, but it does not remove questions around comparative efficacy, reimbursement, supply, clinician adoption or the additional evidence that larger regulatory markets may require.
What makes the UAE authorization the broadest regulatory label yet granted for ANKTIVA?
The Emirates Drug Establishment authorized two separate ANKTIVA presentations with distinct routes of administration and indications. The 0.4 mg formulation is intended for intravesical administration with BCG in BCG-unresponsive non-muscle invasive bladder cancer. The 1.2 mg presentation is intended for subcutaneous administration with an immune checkpoint inhibitor in metastatic non-small cell lung cancer after progression on standard treatment.
Within bladder cancer, the most consequential part of the UAE label is its inclusion of papillary tumors without carcinoma in situ. Patients covered by the authorization can have carcinoma in situ alone, carcinoma in situ accompanied by papillary tumors or papillary-only disease.
That distinction matters because the United States Food and Drug Administration’s existing ANKTIVA label covers carcinoma in situ with or without papillary tumors. A patient with papillary-only BCG-unresponsive disease is outside the present U.S. indication, although the United States regulator has accepted ImmunityBio’s supplemental Biologics License Application seeking that expansion.
The company has said the UAE authorizations were first registered on July 24, 2026, and remain valid until July 2031. ImmunityBio is the marketing authorization holder, while Modern Pharmaceutical Company will serve as the local agent, giving the biotechnology company an established regional route for regulatory coordination and potential distribution.
The decision makes the UAE the fifth major jurisdiction to authorize ANKTIVA, following the United States, United Kingdom, European Union and Saudi Arabia. Because the European Union authorization spans multiple member states, ImmunityBio describes ANKTIVA as authorized across a global footprint of 34 countries.
How persuasive is the QUILT-3.032 evidence behind the expanded bladder cancer label?
The bladder cancer authorization is supported by QUILT-3.032, a multicentre, open-label and single-arm study evaluating ANKTIVA with BCG in patients whose high-risk non-muscle invasive bladder cancer had become unresponsive to BCG treatment.
In the carcinoma in situ cohort of 100 patients, ImmunityBio reported a complete response rate of 71%, with a 95% confidence interval ranging from 61% to 80%. Among the 71 patients who achieved a complete response, the reported median duration of response was 26.6 months. Some responses remained ongoing beyond 54 months.
The company reported that 66% of responders remained in complete response at 12 months and 42% remained in complete response at 24 months. These durability findings are clinically relevant because the principal treatment tension in BCG-unresponsive disease is not merely whether a response can be induced, but whether it can be sustained without allowing potentially dangerous progression while cystectomy is deferred.
The papillary-only cohort included 80 patients. ImmunityBio reported a 12-month disease-free survival rate of 58.2% and median disease-free survival of 25.3 months. The estimated cystectomy-free rate was 92.2% at 12 months and 83.1% at 36 months.
Those findings explain why the UAE regulator was prepared to include papillary-only disease, but the design limits the conclusions that can be drawn. QUILT-3.032 did not randomly assign patients to ANKTIVA plus BCG or a contemporary control treatment. The absence of a control arm makes it difficult to determine precisely how much of the outcome resulted from ANKTIVA, BCG retreatment, patient selection, subsequent care or differences in assessment.
ImmunityBio reported that most treatment-related adverse events across the programme were Grade 1 or Grade 2. Grade 3 treatment-related events occurred in approximately 1% of patients, with no Grade 4 or Grade 5 treatment-related events reported in the disclosed analysis. This provides a useful tolerability signal, although post-authorization use will be important for understanding performance across a broader and potentially less-selected population.
The decision to preserve the bladder must also remain clinically disciplined. The U.S. prescribing information warns that delaying cystectomy can permit progression to muscle-invasive or metastatic bladder cancer, which can be lethal. ANKTIVA’s commercial value will therefore depend partly on whether clinicians can identify appropriate patients, monitor response closely and move to surgery when bladder-preserving treatment is no longer controlling the disease.
Why does the metastatic lung cancer indication carry greater evidence uncertainty?
The UAE’s authorization of ANKTIVA in metastatic non-small cell lung cancer is arguably the more strategically ambitious part of the announcement. It extends the drug beyond intravesical bladder cancer treatment into systemic oncology and supports ImmunityBio’s broader thesis that interleukin-15 stimulation could restore immune activity after resistance to checkpoint inhibitors develops.
The label covers adults with metastatic non-small cell lung cancer whose disease has progressed on or after standard treatment involving an immune checkpoint inhibitor alone or combined with chemotherapy. Patients whose tumors contain actionable genomic alterations must first have progressed on an approved targeted treatment for those alterations.
ANKTIVA is administered with a checkpoint inhibitor as a fixed 1 mg subcutaneous dose once every 21 days for the duration of checkpoint inhibitor therapy. This creates a substantially different treatment and commercial model from intravesical administration in bladder cancer.
The authorization is supported by QUILT-3.055, a Phase 2 study involving 79 patients with advanced non-small cell lung cancer that had progressed following checkpoint inhibitor treatment. ImmunityBio reported median overall survival of 14.6 months, with a 95% confidence interval of 12.0 to 19.5 months.
The company also analysed outcomes according to absolute lymphocyte count. Among patients with a mean on-treatment absolute lymphocyte count of at least 1,000 cells per microlitre, median overall survival was reported at 16.2 months, compared with 11.8 months among patients below that threshold.
This biomarker-associated observation may support the biological rationale for ANKTIVA, but it should not be interpreted as proof that raising lymphocyte counts caused the survival difference. The analysis divides patients according to a biological measure observed during treatment, meaning baseline characteristics, disease burden and treatment response could also influence the association.
The larger limitation is the single-arm design. Without randomization against checkpoint inhibitor continuation, chemotherapy or another accepted treatment strategy, the reported overall survival cannot establish comparative superiority. Cross-trial comparisons are particularly unreliable in previously treated metastatic lung cancer because outcomes vary according to histology, molecular alterations, prior regimens, performance status and the number of previous treatment lines.
The disclosed safety profile was dominated by injection-site and immune-activation symptoms. ImmunityBio reported injection-site reactions in 86% of participants, chills in 46%, fatigue in 32%, fever in 28% and nausea in 16%. These events may be manageable in specialist oncology settings, but the frequency of local reactions and systemic symptoms could affect adherence and treatment experience if use expands.
Saudi Arabia and the UAE have now provided ANKTIVA with regulatory pathways in metastatic lung cancer. The product remains unapproved for lung cancer in the United States, where a larger or more controlled evidence package may be required before the indication can advance.
Can ImmunityBio turn authorization into routine oncology use across the Gulf region?
Marketing authorization removes a central regulatory barrier, but it does not automatically secure reimbursement, hospital procurement or meaningful patient volumes. ImmunityBio and Modern Pharmaceutical Company must now convert the label into pricing agreements, product availability, treatment-centre access and clinician familiarity.
The bladder cancer indication requires dependable access to BCG. Global BCG availability has periodically been constrained, creating a supply risk for any therapy that must be administered in combination with it. Even where ANKTIVA itself is available, shortages or uneven distribution of BCG could restrict the number of patients able to receive the authorized regimen.
Intravesical administration also depends on urology infrastructure. Patients require catheter-based delivery, repeated visits, surveillance cystoscopy and timely evaluation of recurrence or progression. This concentrates adoption among hospitals and clinics with experienced urologic oncology teams.
The metastatic lung cancer formulation presents a different operating challenge. Subcutaneous dosing may simplify administration compared with some intravenous therapies, but ANKTIVA must be coordinated with checkpoint inhibitor treatment in a heavily pretreated population. Hospitals will need prescribing protocols, adverse-event management processes and clarity on which checkpoint inhibitor combinations are reimbursed.
Pricing and reimbursement will be decisive. The company’s announcement did not disclose a UAE list price, reimbursement decision or commercial launch date. The first measurable commercial milestones will therefore be formulary access, initial hospital orders, treatment-centre activation and evidence that regional supply can be maintained.
How does the UAE decision strengthen ImmunityBio’s international regulatory strategy?
The UAE authorization provides ImmunityBio with an important precedent for three elements of its strategy: papillary-only bladder cancer, systemic ANKTIVA dosing and treatment following checkpoint inhibitor failure.
In the United States, the Food and Drug Administration accepted the company’s supplemental application for papillary-only BCG-unresponsive bladder cancer in May 2026 and assigned a target action date of January 6, 2027. The regulator indicated that its review would examine whether scientific similarities between papillary disease and carcinoma in situ justify extrapolating evidence across the populations.
The agency also reiterated concerns associated with relying on a single-arm study in papillary-only disease. The UAE authorization does not determine the U.S. outcome, but it gives ImmunityBio another regulatory decision that management can reference as it advances discussions in other markets.
The international expansion also increases the importance of precise jurisdictional communication. ANKTIVA’s indication is not uniform worldwide. It is approved in the United States only with BCG for BCG-unresponsive non-muscle invasive bladder cancer involving carcinoma in situ, with or without papillary tumors. The United States label does not currently cover papillary-only disease or metastatic lung cancer.
That distinction is especially relevant because the United States Food and Drug Administration has previously objected to promotional materials that it considered broader than ANKTIVA’s approved U.S. uses. ImmunityBio will need to ensure that global announcements and commercial campaigns clearly separate what is authorized in the UAE and Saudi Arabia from what is permitted under the U.S. label.
What does the ANKTIVA authorization mean for ImmunityBio’s revenue and stock sentiment?
ImmunityBio entered this regulatory expansion with growing product revenue from the U.S. bladder cancer launch. The company reported approximately $44.2 million in first-quarter 2026 net product revenue, representing growth of about 168% from the corresponding period of 2025. Full-year 2025 ANKTIVA net product revenue was approximately $113 million.
Cash and marketable securities stood at approximately $381 million at the end of the first quarter, providing resources for manufacturing, international commercialization, regulatory submissions and continued clinical development. The pace of spending will remain important because ImmunityBio is building infrastructure across several countries while financing a broad immunotherapy pipeline.
ImmunityBio shares were trading at about $6.83 in late July, giving the company a market capitalization of approximately $7 billion. The stock’s 52-week range extended from roughly $1.95 to $12.43, illustrating the wide gap between investor optimism surrounding ANKTIVA’s potential and concerns around regulatory, financial and execution risk.
The shares had weakened by approximately 22% from their June 30 close and entered the announcement after several consecutive declining sessions. The UAE authorization is therefore a positive regulatory catalyst, but the valuation will increasingly depend on revenue conversion rather than the number of countries listed in the approval footprint.
Investors will want to see whether international launches generate material sales beyond the existing United States bladder cancer franchise. Approval across 34 countries creates reach, but revenue requires reimbursement, inventory, distribution, patient identification and sustained prescribing.
Which milestones will determine whether the UAE authorization becomes commercially meaningful?
The immediate tests are practical rather than scientific. ImmunityBio and Modern Pharmaceutical Company must establish UAE launch timing, secure pricing and reimbursement arrangements, activate treatment centres and maintain sufficient supplies of both ANKTIVA and BCG.
The papillary-only bladder cancer label will also be watched for real-world evidence of recurrence control, cystectomy avoidance and appropriate surgical referral. Longer follow-up and post-authorization experience will matter because delaying cystectomy in patients whose disease is not responding can carry serious consequences.
For metastatic lung cancer, the central question is whether controlled studies can confirm the survival signal suggested by QUILT-3.055. Regulatory acceptance in Saudi Arabia and the UAE validates a route to regional commercialization, but randomized evidence would provide a stronger foundation for broader adoption and submissions in major Western markets.
The January 6, 2027 U.S. target date for the papillary-only supplemental application is another important catalyst. A positive decision would narrow the gap between the UAE and U.S. bladder cancer labels and expand ImmunityBio’s addressable U.S. population. A negative or restrictive outcome would underline the different evidentiary standards regulators may apply to the same single-arm dataset.
The UAE authorization gives ImmunityBio its widest ANKTIVA label and a credible opportunity to build a Gulf oncology franchise spanning bladder and lung cancer. The harder phase now begins: demonstrating that regulatory breadth can translate into reimbursed access, repeat prescribing, reliable supply and evidence strong enough to support expansion into larger markets.
